Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a Phase III, randomized, placebo-controlled trial

This is the largest interventional clinical study performed in patients with HES to date and demonstrates for the first time that mepolizumab is associated with a reduction in disease flares without significant adverse events.

Source: Journal of Allergy and Clinical Immunology - September 16, 2020 Category: Allergy & Immunology Authors: Florence Roufosse, Jean-Emmanuel Kahn, Marc E. Rothenberg, Andrew J. Wardlaw, Amy D. Klion, Suyong Yun Kirby, Martyn J. Gilson, Jane H. Bentley, Eric S. Bradford, Steven W. Yancey, Jonathan Steinfeld, Gerald J. Gleich Source Type: research